Dichloroacetate (DCA) for Stage IV Cancer
Also known as: DCA, Sodium dichloroacetate
DCA directly reverses the Warburg effect — the metabolic hallmark of cancer — by forcing mitochondrial oxidation over glycolysis.
Mechanism of Action
DCA inhibits pyruvate dehydrogenase kinase (PDK), reactivating pyruvate dehydrogenase and shifting cancer cell metabolism from glycolysis to mitochondrial oxidative phosphorylation. This reversal restores mitochondrial apoptotic signaling, increases ROS production, and opens mitochondrial transition pores — all suppressed by the Warburg phenotype.
General mechanism: PDK inhibitor. Reactivates pyruvate dehydrogenase to reverse Warburg effect. Forces mitochondrial oxidation in cancer cells.
Current Evidence
Phase I/II trials for glioblastoma and other solid tumors show safety and preliminary efficacy signals. Peripheral neuropathy is the dose-limiting toxicity. Used off-label in some integrative oncology protocols. Combination with ketogenic diet is theoretically attractive.
Clinical Status: Phase I/II for glioblastoma and solid tumors. Not FDA-approved for cancer. Off-label use in some countries.
Safety Profile
Peripheral neuropathy is dose-limiting. Sedation and GI effects. Requires monitoring. Contraindicated in mitochondrial disease.
Key Research Questions
- Can DCA + ketogenic diet provide synergistic metabolic cancer therapy?
- What tumor metabolic subtypes (PET-avid vs. non-avid) best predict DCA response?
- Does DCA sensitize tumors to conventional chemotherapy or immunotherapy?